

Prior Authorization Review Panel

CHC-MCO Policy Submission

A separate copy of this form must accompany each policy submitted for review.
Policies submitted without this form will not be considered for review.

Plan: PA Health & Wellness	Submission Date: 9/1/2022
Policy Number: PA.CP.MP.149	Effective Date: 06/2018 Revision Date: 8/24/2022
Policy Name: Testing for Rupture of Fetal Membranes	HC Approval Date:
Type of Submission – Check all that apply: ☐ New Policy ☐ Revised Policy* ☒ Retiring Policy – <i>This option indicates the retirement of an active policy. If there is no indicated replacement, then “NONE” will be listed as the New/Replacement Policy.</i> ☐ Annual Review – No Revisions ☐ Statewide PDL - <i>Select this box when submitting policies for Statewide PDL implementation and when submitting policies for drug classes included on the Statewide PDL.</i>	
*All revisions to the policy <u>must</u> be highlighted using track changes throughout the document. Please provide any changes or clarifying information for the policy below: Please retire this policy – no replacement indicated	
Name of Authorized Individual (Please type or print): Carla Huitt, MD MPH	Signature of Authorized Individual: 

CLINICAL POLICY

Rupture of Fetal Membranes Testing

Clinical Policy: Testing for Rupture of Fetal Membranes

Reference Number: PA.CP.MP.149

Effective Date: 05/18

Last Review Date: 09/18

[Coding Implications](#)

[Revision Log](#)

Description

Premature rupture of membranes is a complication in pregnancy that can lead to preterm delivery. The purpose of this policy is to define medical necessity criteria for testing for rupture of fetal membranes using AmniSure[®], Actim[®] PROM and the ROM Plus Fetal Membranes Rupture Test for the diagnostic evaluation for premature rupture of membranes.

Policy/Criteria

It is the policy of PA Health & Wellness that AmniSure, Actim PROM and the ROM Plus Fetal Membranes Rupture Test (tests billed with CPT[®] code 84112) are considered **not medically necessary** for members as they have not been shown to improve clinical outcomes over standard methods of diagnosis.

Background

Preterm delivery is a major contributing factor to perinatal morbidity and mortality. According to the American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin: Prelabor Rupture of Membranes, premature rupture of membranes (PROM) complicates approximately 2-3% of all pregnancies in the United States.¹ Membrane rupture prior to 37 weeks of gestation is referred to as preterm PROM. There are many pathologies that can influence PROM, although intraamniotic infection is commonly related to preterm PROM.¹

PROM is diagnosed through several methods, including: (1) the visualization of amniotic fluid pooling in the vagina from the cervical canal; (2) a pH test of the vaginal fluid; (3) ferning of dried vaginal fluid through microscopic evaluation.^{1,9} The pH of normal vaginal secretions is 3.8-4.5, whereas the pH of amniotic fluid is 7.1 – 7.3.⁹ According to an ACOG Practice Bulletin, several commercially available tests for amniotic proteins report high sensitivity for PROM. However, false-positive test result rates of 19–30% have been reported in patients with clinically intact membranes and symptoms of labor. ACOG notes that the studies evaluating these protein tests are problematic because most of them use conventional clinical assessment (pooling, ferning, pH) as controls or gold standards for the diagnosis of rupture of membranes, calling into question their utility in equivocal cases.⁹

According to the U.S. Food and Drug Administration, health care providers should not use these tests without other clinical assessments because of concerns about “misuse, overreliance, and inaccurate interpretation of lab test results from rupture of membranes tests used to detect rupture of membranes in pregnant women. These can lead to serious adverse events, including fetal death, infection, and other health complications in pregnant women.”¹⁰

CLINICAL POLICY

Rupture of Fetal Membranes Testing

Per ACOG, if the diagnosis remains unclear after a full evaluation, and if the benefits of the procedure outweigh the risks, membrane rupture can be diagnosed with ultrasonographically guided transabdominal instillation of indigo carmine dye, followed by the passage of blue-dyed fluid into the vagina, which is documented by a stained tampon or pad that is removed 20–30 minutes later. It is important to note that maternal urine also will turn blue or blue-green and should not be confused with amniotic fluid. Recent shortages of indigo carmine dye have complicated the availability of this procedure, and alternatives, such as fluorescein, have been suggested.⁹

The AmniSure test measures the presence of placental alpha macroglobulin-1 (PAMG-1) protein in the amniotic fluid using an immunochromatographic assay from a vaginal swab. This test has been reported to have a high sensitivity for detecting the PAMG-1 protein.² However, the clinical significance of the positive outcomes reported in other studies (evaluating women with term labor and women with preterm labor) should be measured against the small sample sizes (n= 125 and n=90), as well as high false positive rates of 19-30%.^{1,3-4}

Actim PROM rapid test detects insulin-like growth factor binding protein-1 (IGFBP-1) present in amniotic fluid as a marker of the presence of amniotic fluid in a cervicogenic sample. IGFBP-2 is synthesized in the fetal liver and detected in the amniotic fluid throughout pregnancy and the rupture of membranes would cause its displacement. Recent studies utilizing this test have reported a sensitivity and a specificity to as low as 89.3 and 82.7%.⁵ Moreover, the positive predictive value of the Actim test was determined to be less than that of the AmniSure test in a recent meta-analysis study.⁶

ROM Plus Fetal Membranes Rupture Test detects the presence of insulin-like growth factor binding protein-1 (IGFBP-1) and alpha fetoprotein (AFP) as markers of membrane rupture. To date, there is a paucity of published studies evaluating the clinical effectiveness of this test.

Coding Implications

This clinical policy references Current Procedural Terminology (CPT®). CPT® is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2020, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manual and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

CPT Codes considered Not Medically Necessary

CPT® Codes	Description
84112	Evaluation of cervicovaginal fluid for specific amniotic fluid protein(s) (eg, placental alpha microglobulin-1 [PAMG-1], placental protein 12 [PP12], alpha-fetoprotein), qualitative, each specimen

CLINICAL POLICY

Rupture of Fetal Membranes Testing

ICD-10-CM Diagnosis Codes that Support Coverage Criteria

ICD-10-CM Code	Description
N/A	

Reviews, Revisions, and Approvals	Date	Approval Date
Policy created	04/18	06/18
References reviewed and updates	09/18	10/18
References reviewed and updated. Specialist review	10/19	
Background updated with no impact to position statement. References reviewed and updated. References reviewed and updated. Specialist review	06/2021	
Please retire this policy – no replacement indicated	8/24/2022	11/10/2022

References

1. American College of Obstetricians and Gynecologists (ACOG) "Practice Bulletin no. 188: Prelabor Rupture of Membranes. Clinical Management Guidelines for Obstetrician-Gynecologists." *Obstet Gynecol.* 2018 Jun;131(6):1163-1164.
2. Cousins LM, Smok DP, Lovett Sm, Poelte DM. AmniSure placental alpha microglubuin-1 rapid immunoassay versus standard diagnostic methods for detection of rupture of membranes. *Am J Perinatol.* 2005; 22: 317- 20.
3. Lee, Seung Mi, et al. "The clinical significance of a positive Amnisure test™ in women with term labor with intact membranes." *The Journal of Maternal-Fetal & Neonatal Medicine* 22.4 (2009): 305-310.
4. Mi Lee, Seung, et al. "The clinical significance of a positive Amnisure test in women with preterm labor and intact membranes." *The Journal of Maternal-Fetal & Neonatal Medicine* 25.9 (2012): 1690-1698.
5. Abdelazim, Ibrahim A. "Insulin-like growth factor binding protein-1 (Actim PROM test) for detection of premature rupture of fetal membranes." *Journal of Obstetrics and Gynaecology Research* 40.4 (2014): 961-967.
6. Palacio, Montse, et al. "Meta-analysis of studies on biochemical marker tests for the diagnosis of premature rupture of membranes: comparison of performance indexes." *BMC pregnancy and childbirth* 14.1 (2014): 183.
7. Espin MS, Hoffman MK Theilen L, Kupchak P. Prospective evaluation of the efficacy of immunoassays in the diagnosis of rupture of the membranes. *J Matern Fetal Neonatal Med.* 2019 Jan 13:1-7.
8. Tchirikov M, Schlabritz-Loutsevitch N, Maher J, et al. Mid-trimester preterm premature rupture of membranes (PPROM): etiology, diagnosis, classification, international recommendations of treatment options and outcome. *J Perinat Med.* 2018 Jul 26;46(5):465-488.
9. American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin no.217, Prelabor Rupture of Membranes March 2020 (Replaces #188, January 2018)

CLINICAL POLICY

Rupture of Fetal Membranes Testing

10. U.S. Food and Drug Administration. Risks associated with use of rupture of membranes tests—letter to health care providers. Silver Spring, MD: FDA; 2018. Available at: <https://www.fda.gov/medical-devices/letters-health-care-providers/risks-associated-use-rupture-membranes-tests-letter-health-care-providers>.
11. Hayes Molecular Assessment. AmniSure ROM Test for Detection of Fetal Membrane Rupture. Mar, 20, 2018. Update May 4, 2020.